Drug resistance, epigenetics, and tumor cell heterogeneity

Science Translational Medicine

Volumn 2, Issue 28, 2010, Pages

  Hoey, Timothy ^a  

^a OncoMed Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; RETINOBLASTOMA BINDING PROTEIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL HETEROGENEITY; CELL PROLIFERATION; CELL RENEWAL; CELL SUBPOPULATION; DNA CROSS LINKING; DRUG MECHANISM; DRUG SENSITIVITY; EMBRYONIC STEM CELL; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETIC EPIGENESIS; GENETIC HETEROGENEITY; GENETICS; MUTATION; NEOPLASMS; PATHOLOGY;

DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77952961537     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001056     Document Type: Short Survey

References (13)

1. S. V. Sharma, D. Y. Lee, B. Li, M. P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M. A. Fischbach, K. K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon, J. Settleman, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
2. D. Bixby, M. Talpaz, Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology (Am. Soc. Hematol. Educ. Program) 2009, 461-476 (2009).
3. J. M. Rosen, C. T. Jordan, The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673 (2009).
4. C. E. Eyler, J. N. Rich, Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26, 2839-2845 (2008).
5. J. Christensen, K. Agger, P. A. Cloos, D. Pasini, S. Rose, L. Sennels, J. Rappsilber, K. H. Hansen, A. E. Salcini, K. Helin, RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 128, 1063-1076 (2007).
6. D. Pasini, K. H. Hansen, J. Christensen, K. Agger, P. A. Cloos, K. Helin, Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2. Genes Dev. 22, 1345-1355 (2008).
7. J. C. Peng, A. Valouev, T. Swigut, J. Zhang, Y. Zhao, A. Sidow, J. Wysocka, Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139, 1290-1302 (2009).
8. X. Shen, W. Kim, Y. Fujiwara, M. D. Simon, Y. Liu, M. R. Mysliwiec, G. C. Yuan, Y. Lee, S. H. Orkin, Jumonji modulates polycomb activity and self-renewal versus diff erentiation of stem cells. Cell 139, 1303-1314 (2009).
9. R. J. Klose, Q. Yan, Z. Tothova, K. Yamane, H. Erdjument-Bromage, P. Tempst, D. G. Gilliland, Y. Zhang, W. G. Kaelin Jr., The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128, 889-900 (2007).
10. K. Polyak, R. A. Weinberg, Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273 (2009).
11. E. J. Robson, W. T. Khaled, K. Abell, C. J. Watson, Epithelialto- mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation 74, 254-264 (2006).
12. T. Hoey, W. C. Yen, F. Axelrod, J. Basi, L. Donigian, S. Dylla, M. Fitch-Bruhns, S. Lazetic, I. K. Park, A. Sato, S. Satyal, X. Wang, M. F. Clarke, J. Lewicki, A. Gurney, DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177 (2009).
13. M. T. Mueller, P. C. Hermann, J. Witthauer, B. Rubio-Viqueira, S. F. Leicht, S. Huber, J. W. Ellwart, M. Mustafa, P. Bartenstein, J. G. D'Haese, M. H. Schoenberg, F. Berger, K. W. Jauch, M. Hidalgo, C. Heeschen, Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137, 1102-1113 (2009).